CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)
Vera Ademà(Cleveland Clinic), Valeria Visconte(Cleveland Clinic), Kevin Fung(Western University), Hetty E. Carraway(Cleveland Clinic), Jennifer S. Carew(University of Arizona), Yogenthiran Saunthararajah(Cleveland Clinic), Christina Snider(Vanderbilt University Medical Center), Manja Meggendorfer(Université Paris-Sud), Torsten Haferlach(Martin Luther Christian University), Michael R. Savona(Vanderbilt University), Francesca Gould(Cleveland Clinic), James G. Phillips(Auckland University of Technology), Mikkael A. Sekeres(University of Miami), Steffan T. Nawrocki(University of Arizona), Stephan Hütter(Munich Leukemia Laboratory (Germany)), Sunisa Kongkiatkamon(Cleveland Clinic), Cassandra M Kerr(Cleveland Clinic), Jibran Durrani(National Institutes of Health), Anjali S. Advani(Cleveland Clinic), Kevin R. Kelly(Keck Hospital of USC), Jaroslaw P. Maciejewski(Cleveland Clinic), Hassan Awada(Cleveland Clinic)
Cited by 0
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k